secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sana Biotechnology, Inc. (SANA)
CIK:        0001770121
Form:       8-K
Filed at:   2022-11-01T23:59:59+00:00
Accession:  0001564590-22-036057
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.05
LLM model:  deepseek-v4-flash:cloud@v2

Sana Biotechnology adopts revised Code of Business Conduct and Ethics with enhanced conflict-of-interest policies
--------------------------------------------------------------------------------

- Board adopted amended Code on October 27, 2022, adding details on potential conflicts of interest.
- Revised Code includes policies and procedures for evaluating conflicts involving Board members.
- No waivers granted; full text available on company's investor relations website.
- Routine governance update with no financial or operational impact.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770121/000156459022036057/0001564590-22-036057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770121/000156459022036057/sana-8k_20221027.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-036057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer